Burnett Patrick, SR, reported an open-market or private sale at Arcutis Biotherapeutics, Inc. involving 3675.000000 shares for an estimated $93706.62. Reported holdings after the transaction were 90445.000000 shares. The stored filing text includes a detected 10b5-1 reference.
Stored Form 4 columns with their raw values
Badges describe filing facts only — not predictions.
Compact filing score computed from stored Form 4 facts. Version v1.
This filing is broadly neutral on the filing-only scale. The Form 4 facts do not strongly tilt positive or negative.
Form 4 relationship flags and nearby filing context
See Remarks
The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligation in connection with the vesting of Restricted Stock Units ("RSUs"), granted on Januar…
The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $24.745 to $25.68, inclusive. The Reporting Person hereby undertak…
The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted on December 12, 2024, by the Reporting Person, with a plan end date of February 27, 2026.
The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $25.58 to $26.09, inclusive. The Reporting Person hereby undertake…
0 other filings
0 recent txs